# CORRESP — ENANTA PHARMACEUTICALS INC  (ENTA)  (CIK 0001177648)

> <strong>ENANTA PHARMACEUTICALS INC  (ENTA)  (CIK 0001177648) → SEC staff</strong> · filed 2026-02-17 · ticker ENTA · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001193125-26-055328
- **Form:** CORRESP
- **Filer:** ENANTA PHARMACEUTICALS INC  (ENTA)  (CIK 0001177648)
- **CIK:** 0001177648
- **Ticker:** ENTA
- **Filed:** 2026-02-17
- **SIC industry:** 2834
- **HQ:** Watertown, MA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1177648/000119312526055328/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1177648&type=UPLOAD&dateb=&owner=include&count=40

## Other comment-letter activity for ENANTA PHARMACEUTICALS INC  (ENTA)  (CIK 0001177648)

- UPLOAD — 2026-02-17 — /comment-letter/0000000000-26-001607

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, ENANTA PHARMACEUTICALS INC  (ENTA)  (CIK 0001177648) (CIK 0001177648), filed 2026-02-17, accession 0001193125-26-055328. Retrieved via MORVS 2026-11-19 from https://api.morvs.ai/comment-letter/0001193125-26-055328.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*
